114 related articles for article (PubMed ID: 11275707)
1. Pancreatic cancer: does octreotide offer any promise?
Rosenberg L
Chemotherapy; 2001; 47 Suppl 2():134-49. PubMed ID: 11275707
[TBL] [Abstract][Full Text] [Related]
2. [Somatostatin receptors--new diagnostic and therapeutic possibilities].
Pawlikowski M
Endokrynol Pol; 2005; 56(1):4-5. PubMed ID: 16335666
[No Abstract] [Full Text] [Related]
3. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer: a review of emerging therapies.
Rosenberg L
Drugs; 2000 May; 59(5):1071-89. PubMed ID: 10852640
[TBL] [Abstract][Full Text] [Related]
5. Octreotide uptake in intracranial metastasis of pancreatic ductal adenocarcinoma origin in a patient with a prolonged clinical course.
Marepaily R; Micheals D; Sloan A; Hatfield J; Adsay V; Joyrich R; Ullah N; Tobi M
Dig Dis Sci; 2009 Jan; 54(1):188-90. PubMed ID: 18985450
[TBL] [Abstract][Full Text] [Related]
6. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors.
Oda Y; Tanaka Y; Naruse T; Sasanabe R; Tsubamoto M; Funahashi H
Surg Today; 2002; 32(8):690-4. PubMed ID: 12181718
[TBL] [Abstract][Full Text] [Related]
7. [Somatostatin analogs in the treatment of pancreatic cancer: utopia or feasible alternative?].
Zalatnai A; Pogány V
Orv Hetil; 2000 Oct; 141(43):2333-8. PubMed ID: 11089387
[TBL] [Abstract][Full Text] [Related]
8. Biotherapeutic approaches to pancreatic cancer.
Rosenberg L; Lipsett M
Expert Opin Biol Ther; 2003 Apr; 3(2):319-37. PubMed ID: 12662145
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
10. [Octreotide in the treatment of advanced pancreatic tumor. Preliminary study].
Cirillo F; Bottini A; Brunelli A; Zuffada S; Bassi M; Filippini L; Alquati P
Minerva Chir; 1998 Dec; 53(12):979-85. PubMed ID: 10210927
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced endocrine gastroenteropancreatic tumours using radiolabelled somatostatin analogues.
Van Eijck CH
Br J Surg; 2005 Nov; 92(11):1333-4. PubMed ID: 16237740
[No Abstract] [Full Text] [Related]
12. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
Butturini G; Bettini R; Missiaglia E; Mantovani W; Dalai I; Capelli P; Ferdeghini M; Pederzoli P; Scarpa A; Falconi M
Endocr Relat Cancer; 2006 Dec; 13(4):1213-21. PubMed ID: 17158766
[TBL] [Abstract][Full Text] [Related]
14. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
15. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
16. Influence of octreotide and tamoxifen on tumor growth and liver metastasis in N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian hamsters.
Wenger FA; Kilian M; Mautsch I; Jacobi CA; Schimke I; Saul GJ; Guski H; Müller JM
Horm Res; 2000; 54(2):74-7. PubMed ID: 11251370
[TBL] [Abstract][Full Text] [Related]
17. [Subcutaneous continuous injection of octreotide decreased the tumor marker levels and induced cystic necrosis of the tumors in a case of pancreatic neuroendocrine tumor with multiple hepatic metastases].
Miura M; Shibahara H; Morita K; Matsui K; Itoh Y; Shimizu J; Takeuchi A; Narita M; Nishimura D; Katada N
Nihon Shokakibyo Gakkai Zasshi; 2015 Mar; 112(3):537-46. PubMed ID: 25759229
[TBL] [Abstract][Full Text] [Related]
18. Octreotide in the management of hormone-refractory prostate cancer.
Vainas IG
Chemotherapy; 2001; 47 Suppl 2():109-26. PubMed ID: 11275705
[TBL] [Abstract][Full Text] [Related]
19. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
Müssig K; Petersenn S; Wehrmann M; Horger M; Vierling P; Häring HU; Gallwitz B
Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):719-23. PubMed ID: 17625444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
